The U.S. Food and Drug Administration's approval of Biogen's Alzheimer's drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands of Americans every year.But the excitement around the first…
The drug maker Biogen said on Wednesday that a panel of drug reviewers in the European Union had indicated that its new Alzheimer’s drug was unlikely to be approved there, the latest setback for a medication that has been mired in…
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, had brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.The sales figures, which Biogen…
Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower risk of relapse for patients…
Aduhelm by BiogenSource: BiogenBiogen's Alzheimer's drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about…
The exterior of the headquarters of biotechnology company Biogen in Cambridge, MA is pictured on March 21, 2019.John Tlumacki | Boston Globe | Getty ImagesA 70-year-old man from Rhode Island on Wednesday was the first person to receive an…
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021.Adam Glanzman | Bloomberg | Getty ImagesBiogen's pricy new Alzheimer's drug, Aduhelm, could cost Medicare billions of dollars a year,…